Tag:
Biocryst
Latest Headlines
Latest Headlines
BioCryst's shares spike on hope that flu drug can rise from the grave
Months after the beleaguered BioCryst Pharmaceuticals ($BCRX) started reading the last rites for its long-running Phase III program for the flu drug peramivir i.v., citing a weak response and the need to add more patients to the study, the biotech has tried to cheer up its battered investors with the news that the therapy may not be completely dead after all.
BioCryst Pharma chops half of staff to cap tumultuous two months
BioCryst Pharmaceuticals ($BCRX) blamed recent setbacks for the company's decision to ax 50% of its workers, according to a release this morning. Its restructuring plans come a week after BioCryst and Presidio Pharmaceuticals jettisoned a $101 million merger agreement that would have brought BioCryst new assets in the sizzling hepatitis C field.
UPDATED: BioCryst Pharma, Presidio ax merger deal after series of setbacks
Ever since BioCryst Pharmaceuticals and Presidio Pharmaceuticals agreed to a $101 million merger deal in October, BioCryst has suffered a string of pipeline disasters. This morning Presidio and BioCryst revealed that the companies have come to a "mutual" decision to kill the merger agreement that was seen as a way for BioCryst to raise its holdings in the hot market for hepatitis C drugs.
BioCryst scraps $235M late-stage flu drug program backed by feds
After this latest setback, the company's chief medical officer says that it is "unlikely" that the biotech will continue development work needed for U.S. approval.
BioCryst scoops up early-stage hep C drugs in $101M Presidio acquisition
The Durham, NC-based BioCryst will gain some early-stage hepatitis C drug components as it absorbs Presidio Pharmaceuticals into the company, which will seek a new identity under a different name. The deal is also tied to a $60 million financing pact.
Hep C drug deal frenzy can't be slowed by growing doubts
At the BIO CEO & Investor Conference in New York yesterday, Achillion CEO Michael Kishbauch wrapped up his remarks on the biotech's hepatitis C programs by making it clear that he was angling for
BioCryst shares surge on positive IIb study for gout drug
Shares of BioCryst Pharmaceuticals ( $BCRX ) bumped up 12% this morning after the biotech unveiled a set of positive top-line data for its mid-stage gout drug. In a 12-week Phase IIb study of BCX4208,
Dendreon releases death-eaters into biotech sector stocks
Wednesday's Dendreon nightmare turned into Thursday's biotech bloodbath. Sector stocks posted "particularly steep losses," said RTT News, dragging down the NYSE Arca Biotechnology Index by 10.6% to
HHS hands BioCryst $55M for Phase III trial
HHS has awarded BioCryst Pharmaceuticals a $55 million contract modification to fund to completion the Phase II development of peramivir for the treatment of patients hospitalized with influenza.
BioCryst shares slide on peramivir trial revisions
Shares of BioCryst Pharmaceuticals slid about eight percent on the news that it wants to expand the size of its late-stage study of its IV formulation of peramivir while altering the endpoint. The
